SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
MEDIAN Technologies (Paris:ALMDT) (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announced today that it will present the results of a study at the International SPIE Medical Imaging conference to be held in San Diego from Feb. 27th to March 3rd.
The extraction and analysis of image features (radiomics) is a promising
field in the precision medicine era, with applications to prognosis,
prediction, and response to treatment quantification. A key aspect of
radiomics is the selection of features, i.e. which features to use for a
specific application. Common criteria such as reproducibility,
independence, and informative power are used to select features.
In this study, we present a method based on information theory to quantify reproducibility. The method measures the common information between measurements obtained by different observers, and allows an intuitive quantification of inter-observer agreement. Results show that the proposed method was able to separate features shown as equivalent by classical methods. Consequently, this novel method enables to better select image features for specific applications.
The study “Mutual Information-based feature selection for radiomics” will be presented during the “Big Data Technologies and Image Sharing in Medical Imaging and Informatics” session to be held on Monday 29 February from 8:00 to 9:40 am PST.
The scientific abstract of the study is available here
(Search keywords: Median Technologies).
More about the SPIE Medical Imaging Conference: http://spie.org/conferences-and-exhibitions/medical-imaging
About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”